Panagene has announced that it has exclusively licensed the right to peptide nucleic acids (PNA) custom synthesis from the Copenhagen Inventor Group (CIG). The agreement allows Panagene to synthesize, ...

HLB PANAGENE's independently developed companion diagnostic product has been approved as the first companion diagnostic medical device in South Korea for the non-small cell lung cancer gene mutation ...

DAEJEON, South Korea--(BUSINESS WIRE)--Panagene announced it has signed a supply agreement with Dako Denmark A/S to supply PNA oligomer key component for incorporation into Dako’s diagnostic or ...

Panagene (046210) has delivered a -39% change over the past year, with a 52-week range between 1,535 and 3,315. What Is the Average Daily Trading Volume of Panagene (046210)? The average daily trading ...

[THE INVESTOR] Korean biotechnology firm Panagene said on Oct. 26 that the country’s health regulator has granted approval for sale of its diagnostics kit for sexually transmitted diseases. The ...

WOBURN, Mass. and DAEJEON, Korea--(BUSINESS WIRE)--Panagene and AdvanDx, Inc. have entered into an exclusive supply agreement under which Panagene will manufacture PNA probes for incorporation into ...

Despite the market volatility, shares in Panagene Inc (KOSDAQ:46210) have been in an uptrend in recent months. The question now for investors is whether that price strength will continue. Finding ...

HLB PANAGENE Co., Ltd. engages in the molecular diagnostics business. The firm is also involved in the development, manufacturing, and sale of peptide nucleic acid (PNA) genetic diagnostic chips. It ...

HLB PANAGENE said on the 4th that three molecular diagnostic reagents for infectious diseases have obtained certification under the European Union (EU) In Vitro Diagnostic Medical Devices Regulation ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for ...